NTM lung disease is a chronic infection caused by nontuberculous mycobacteria, a group of bacteria found naturally in soil, dust, and water. Unlike tuberculosis, which spreads between people, NTM infections come from the environment and are not contagious. The disease is rising in prevalence across the United States, Canada, and parts of Europe, where it now outnumbers tuberculosis cases in some regions.
How NTM Bacteria Enter the Lungs
Nontuberculous mycobacteria are everywhere in the environment. They live in rivers, streams, municipal tap water, and the moist surfaces inside household plumbing. Showerheads, sink faucets, and hot tubs are common reservoirs. When contaminated water turns into a fine mist or spray, the bacteria become airborne, and people inhale them.
Once inhaled, the bacteria typically settle in the lower airways. In most healthy people, the immune system clears them without trouble. But in people with vulnerable lungs or weakened immunity, the bacteria can take hold and trigger an inflammatory response. Immune cells flood the area, releasing chemical signals that cause tissue damage and produce symptoms resembling pneumonia. Over time, this ongoing inflammation can scar and permanently damage lung tissue.
Because NTM infections come from environmental exposure rather than person-to-person contact, you cannot catch it from a family member, coworker, or anyone else who has it. This is a key difference from tuberculosis, which is highly contagious through airborne droplets.
Who Is Most at Risk
NTM bacteria are common, but the disease is not. Most people breathe in these organisms without ever getting sick. The infection tends to develop in people whose lungs are already compromised or whose immune systems are suppressed.
Pre-existing lung conditions are the biggest risk factor. People with bronchiectasis (permanently widened airways that trap mucus), emphysema, or cystic fibrosis are particularly susceptible because their airways have a harder time clearing bacteria. Older adults face higher risk as well, partly because lung function and immune defenses decline with age. People who are immunocompromised, whether from medication, HIV, or other conditions, are also more vulnerable.
There is a well-known clinical profile sometimes called “Lady Windermere syndrome”: tall, thin, postmenopausal women with no obvious underlying lung disease who develop NTM infections. The reasons are not fully understood, but this group makes up a notable portion of patients.
Symptoms and How the Disease Progresses
NTM lung disease tends to develop slowly, and its symptoms overlap with many other respiratory conditions, which makes early recognition difficult. The most common signs include a persistent cough that lasts weeks or months, fatigue, unintended weight loss, shortness of breath, increased mucus production, and night sweats. Some people cough up blood. These symptoms often come on gradually, and patients may attribute them to aging or a lingering cold before seeking evaluation.
Chronic NTM infection affects the lungs of roughly 94% of patients and causes progressive damage over time. The disease takes two main forms visible on CT imaging. The less severe form, called nodular bronchiectasis, involves small nodules scattered through the lungs alongside widened airways. The more severe form is cavitary lung disease, where ongoing scarring creates hollow spaces, usually in the upper lobes. Cavitary disease carries a higher risk of respiratory failure if untreated.
How NTM Lung Disease Is Diagnosed
Diagnosis is not straightforward. Simply finding NTM in a sputum sample does not mean you have the disease, because these bacteria are so common in the environment that a single positive culture could be a contaminant. The American Thoracic Society and the Infectious Diseases Society of America established guidelines requiring three types of evidence, all of which must be met: clinical symptoms, characteristic findings on chest imaging (typically a high-resolution CT scan), and microbiological confirmation from multiple sputum cultures.
The microbiological bar is deliberately high. Doctors generally need at least two positive sputum cultures taken on separate occasions, or a positive culture from a lung tissue biopsy, to confirm the diagnosis. This process can take weeks to months because mycobacteria grow slowly in the lab.
Which Bacteria Cause It
Over 200 species of nontuberculous mycobacteria exist, but only a handful cause the majority of lung infections. The most common culprit by a wide margin is Mycobacterium avium complex, or MAC, which accounts for roughly two-thirds of confirmed cases. MAC thrives in household water systems and is the species most often linked to showerhead exposure.
Other clinically significant species include Mycobacterium abscessus, which is found in water, soil, and dust, and is notoriously difficult to treat because of its natural resistance to many antibiotics. Mycobacterium kansasii is another important species that tends to respond somewhat better to treatment. The specific species matters because it determines which antibiotics will work and how long treatment needs to last.
Treatment and What to Expect
Treating NTM lung disease is a long commitment. The standard approach for MAC infections, the most common type, involves a combination of three antibiotics taken together. Treatment does not stop when you start feeling better. Current guidelines recommend continuing antibiotics for at least 12 months after your sputum cultures convert to negative, meaning three consecutive monthly cultures show no bacteria. In practice, this means most patients are on treatment for 18 months or longer.
The extended timeline reflects how stubborn these bacteria are. Unlike a typical bacterial infection that clears in a week or two of antibiotics, mycobacteria grow slowly and hide within immune cells, requiring prolonged drug exposure to eliminate. Culture conversion itself is defined as three consecutive negative sputum samples collected at least four weeks apart, so even confirming the infection is clearing takes months of monitoring.
For patients whose infections do not respond to standard therapy after at least six months, there is an inhaled antibiotic option approved by the FDA specifically for refractory MAC lung disease. It is reserved for adults who have limited or no alternative treatment options and is used alongside other antibiotics, not alone. This approval was based on the drug’s ability to achieve culture conversion, and it reflects how difficult some NTM infections are to control.
Cavitary disease and infections caused by Mycobacterium abscessus tend to be harder to treat and may require longer courses, different drug combinations, or in some cases surgical removal of the most damaged portion of lung. Even after successful treatment, recurrence is possible because patients remain exposed to the same environmental sources.
Living With NTM Lung Disease
Because NTM bacteria are ubiquitous in the environment, completely avoiding exposure is unrealistic. However, some practical steps can reduce bacterial load at home. Cleaning and replacing showerheads regularly, avoiding hot tubs, and using point-of-use water filters can lower the concentration of NTM in aerosolized water. For people who garden, wearing a mask while handling potting soil or compost reduces inhalation of contaminated dust.
The disease takes a significant toll on quality of life. Chronic cough, fatigue, and the side effects of months-long antibiotic therapy can be draining. Weight loss is common and sometimes severe, making nutritional support an important part of overall management. Many patients benefit from pulmonary rehabilitation, which combines supervised exercise with breathing techniques to maintain lung function during and after treatment.
NTM lung disease remains, in the words of researchers, “poorly understood,” with a limited evidence base to guide prevention and treatment compared to tuberculosis. Annual incidence continues to climb by roughly 4 to 5% per year in countries that track it. For patients navigating a diagnosis, connecting with a pulmonologist who has specific experience treating NTM infections can make a meaningful difference in outcomes.